EGFR and lung adenocarcinoma: In conclusion, we pointed out that re-administration of EGFR-TKI and cytotoxic chemotherapy shared the similar clinical efficacy in third-line therapy in patients who had lung adenocarcinoma initially harbored susceptible EGFR mutation, if the 3rdEGFR TKI is not available, unknown resistance mechanism or not related to T790M mutation.